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For successful therapy, hepatocellular carcinoma (HCC) must be detected at an early stage. Herein, we used a proteomic ap-
proach to analyze the secretory/releasing proteome of HCC tissues to identify plasma biomarkers. Serum-free conditioned me-
dia (CM) were collected from primary cultures of cancerous tissues and surrounding noncancerous tissues. Proteomic analysis 
of the CM proteins permitted the identification of 1365 proteins. The enriched molecular functions and biological processes of 
the CM proteins, such as hydrolase activity and catabolic processes, were consistent with the liver being the most important 
metabolic organ. Moreover, 19% of the proteins were characterized as extracellular or membrane-bound. For validation, se-
cretory proteins involved in transforming growth factor-β signaling pathways were validated in plasma samples. Alpha-    
fetoprotein (AFP), metalloproteinase (MMP)1, osteopontin (OPN), and pregnancy-specific beta-1-glycoprotein (PSG)9 were 
significantly increased in HCC patients. The overall performance of MMP1 and OPN in the diagnosis of HCC remained great-
er than that of AFP. In addition, this study represents the first report of MMP1 as a biomarker with a higher sensitivity and 
specificity than AFP. Thus, this study provides a valuable resource of the HCC secretome with the potential to investigate se-
rological biomarkers. MMP1 and OPN could be used as novel biomarkers for the early detection of HCC and to improve the 
sensitivity of biomarkers compared with AFP.  
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Approximately 600000 new cases of hepatocellular carci-
noma (HCC) are diagnosed each year, of which approxi-
mately 55% are detected in China [1]. The relationship be-
tween HCC and persistent hepatitis B virus (HBV) infection 
has been well documented. More than 20 million individu-
als suffer from chronic HBV infection in China [2]. Surgical  
resection is the most effective treatment for HCC patients, 
but the reported five-year disease-free survival rate is only 
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25%30% [34]. The majority of HCC diagnoses usually 
occur at a late stage, resulting in poor prognoses. Al-
pha-fetoprotein (AFP) has been widely used for high-risk 
population screening, in combination with ultrasound im-
aging. However, its limited performance and sensitivity of 
39%65% are not sufficient for accurate screening [5]. 
Thus, improvements in the early detection and more accu-
rate markers are urgently needed.  
Proteomics analysis has provided critical and specific 
information regarding the functional and structural activities 
of proteins in organisms. One major challenge in plasma 
proteomics is the large dynamic range of protein abundanc-
es, from mg mL1 to pg mL1 or lower [6]. A small number 
of high-abundance proteins mask the majority of low- 
abundance proteins. To address this problem, several ap-
proaches have used affinity-based depletion, ultracentrifu-
gation, or precipitation to remove the most abundant pro-
teins from samples. Unfortunately, these methods have low 
reproducibility, low specificity, or low-throughput and are 
thus not suitable for identifying novel proteins [7]. Because 
of the formidable challenges of direct analysis of plasma/ 
serum samples, the secretome has been pursued as an alter-
native approach for blood biomarker discovery. Secreted 
proteins are also most likely excellent candidate serological 
tumor markers because they are released by cells and thus 
have the highest potential to enter the circulation [8]. For 
example, Planque et al. [9] identified five biomarker candi-
dates in plasma by analyzing conditioned media (CM) from 
four lung cancer cell lines. Polisetty et al. [10] constructed a 
secretome of three glioblastoma cell lines and demonstrated 
that 22 proteins were detectable in plasma. However, few 
reports have focused on the HCC secretome for screening 
biomarkers in blood.  
Cell-based systems for proteomics analysis have emer- 
ged as a time- and cost-effective platform for identifying 
biomarkers. Nevertheless, the discrepancy between immor-
talized cancer cells and clinical samples may be considera-
ble. Therefore, we previously developed a novel approach 
based on the primary culture of tumor tissues and proteomic 
analysis of serum-free CM [11,12]. In this study, we col-
lected serum-free CM from cultures of cancerous and sur-
rounding noncancerous tissues from six HCC patients with 
HBV infection. Proteins in the CM were investigated by 
MS-based proteomic analysis to establish a high-quality 
secretory/releasing proteome of HCC. We then validated 
AFP and biomarker candidates including matrix metallo-
proteinase (MMP)1, MMP7, MMP9, osteopontin (OPN), 
pregnancy-specific beta-1-glycoprotein (PSG)9, and tissue 
inhibitor of metalloproteinase (TIMP)1 in human plasma 
and evaluated their performance for the diagnosis of HCC. 
1  Materials and methods 
1.1  Patients and specimens 
Primary tissue cultures, including cancerous and surround-
ing noncancerous tissue samples, were obtained from six 
primary HCC patients. All patients were HBV carriers who 
underwent surgical resection in March 2009 at the Cancer 
Hospital, Peking Union Medical College (PUMC), Chinese 
Academy of Medical Sciences (CAMS). The histological 
diagnosis of the tissue samples was confirmed by experi-
enced pathologists. The corresponding clinicopathological 
factors are described in Table S1 in Supporting Information. 
HCC plasma was collected from 179 HCC patients (35 
females and 144 males, with a mean age of 54.0 years) be-
fore hepatectomy at the Cancer Hospital, PUMC & CAMS. 
All HCC patients were chronically infected with HBV. Cir-
rhosis plasma was obtained from 80 liver cirrhosis patients 
(24 females and 56 males, with a mean age of 53.5 years) 
with chronic HBV infection at Beijing You’an Hospital, 
Capital Medical University. Healthy plasma from 103 
healthy controls without HBV infection (13 females and 90 
males, with a mean age of 49.1 years) was obtained from a 
health screening program at the Cancer Hospital. Peripheral 
blood was obtained as described previously [12]. All tissue 
and plasma samples were collected with informed consent 
and approval of the Institute Ethics Committee. 
1.2  Primary organ culture and conditioned medium 
harvest 
Primary organ cultures were based on six paired tissues 
containing cancerous and surrounding noncancerous tissues 
from HCC patients subjected to hepatectomy. The freshly 
obtained tissue samples were rinsed, cut into 23 mm3 piec-
es, and transferred to 60 mm culture dishes. The explants 
were cultivated at 37°C in LHC-9 medium (serum-free) [13] 
in a gas mixture of 50% O2, 45% N2, and 5% CO2. Hank’s 
solution was used to wash the cultures 24 h later. The ex-
plants were then cultivated in serum-free LHC-9 without 
bovine pituitary extract for another 24 h. The CM was then 
collected and dialyzed with an Amicon Ultra-15 centrifugal 
filter device (Millipore, Billerica, MA, USA). 
1.3  One-dimensional sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and liquid 
chromatography-mass spectrometry (LC-MS)/MS anal-
ysis of CM proteins 
CM samples containing 50 μg of total protein were subject-
ed to 10% SDS-PAGE. After staining with Coomassie blue, 
40 bands were excised from the gel lanes and tryp-
sin-digested according to Zhang et al. [12]. Then, nano-LC- 
MS/MS was conducted with a SYNAPT system (Waters, 
MA, USA). Each peptide mixture extract was dissolved in  
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6 μL 0.1% formic acid and separated on a nano-ACQUITY 
system (Waters) equipped with a Symmetry C18 pre-  
column and an ethylene bridged hybrid (EBH) C18 analyti-
cal reversed-phase column. The samples were transferred 
from an aqueous 0.1% formic acid solution to the 
pre-column at a rate of 7 μL min1 for 3 min. The solvents 
used were aqueous 0.1% formic acid (v/v) (A) and 0.1% 
formic acid (v/v) in acetonitrile (B) with a linear gradient of 
97%60% mobile phase A in mobile phase B over 90 min 
at 200 nL min1, followed by 10 min of 10% mobile phase 
A and 90% mobile phase B. The lock mass was delivered to 
the nano-ACQUITY auxiliary pump with a constant flow of 
300 nL min1 at a concentration of 100 fmol μL1 
Glu-fibrinopeptide B. Then, the tryptic peptides were ana-
lyzed on a SYNAPT high-definition mass spectrometer [14]. 
The mass spectrometer was operated in the v-mode, at least 
10000 full-width half maximum. The TOF analyzer of the 
mass spectrometer was calibrated with MS/MS fragment 
ions of Glu-fibrinopeptide B from m/z 50 to 1600. The 
sprayer was sampled with a frequency of 30 s. Accurate 
mass LC-MS data were collected in the high-definition 
MSE mode (low collision energy 4 eV, high collision ener-
gy, ramping from 15 to 45 eV, switching every 1 s, with an 
interscan time of 0.02 s). The mass range was from 300 to 
1990 m/z. 
1.4  CM protein identification  
The protein-Lynx Global Server version 2.3 (Waters) was 
used to generate peak list files for the SYNAPT spectra. 
Those files were then searched against UniProt (human, 
76137 entries; UniProt Knowledgebase Release 12.6 con-
sists of UniProtKB/Swiss-Prot Release 54.6 from December 
4, 2007) using the pFind 2.4 search program. In all database 
searches, trypsin was designated as the protease, and only 
one missed cleavage was allowed. The maximal mass tol-
erance was set at 0.2 Da for the precursor ions and 0.3 Da 
for the fragment ions. Carbamidomethylation (Cysteine) 
was searched as a fixed modification. Oxidation (methio-
nine) was set as a variable modification. The overall number 
of false positives can be estimated by doubling the number 
of peptides found from the reverse sequences. A peptide 
false discovery rate (FDR) lower than 1% was applied. The 
pFind 2.4 program provides a fully automated method. Fi-
nally, the remaining peptides were identified according to 
the protein inference algorithm . 
1.5  Measurement of the CM proteins in plasma 
All experimental procedures were performed according to 
the manufacturer’s instructions. AFP levels were tested us-
ing a commercial immunoassay with enhanced chemilumi-
nescence at the Clinical Diagnostic Laboratories of the 
Cancer Hospital, Chinese Academy of Medical Sciences. 
The levels of six other selected CM proteins (MMP1, 
MMP7, MMP9, OPN, PSG9 and TIMP1) were evaluated by 
double-antibody sandwich enzyme-linked immunosorbent 
assay (ELISA). All ELISA kits were obtained from com-
mercial manufacturers (R&D, Minneapolis, MN, USA) ex-
cept PSG9 (Blue Gene, Shanghai, China).  
1.6  Bioinformatics analysis 
Gene ontology (GO) enrichment was performed using 
GOFFA tools [15]. The ArrayTrack Pathway tool was ap-
plied to extract the biological associations of the CM pro-
teins using public databases, including the KEGG and 
PATHART databases [15]. The CM protein networks were 
analyzed using STRING online tools. The Mann-Whitney 
U-test (SPSS version 17.0, Chicago, IL, USA) was used to 
compare the differences in the plasma levels of selected 
proteins. Receiver operating characteristic (ROC) curves 
and the area under the ROC (AUC) calculations were per-
formed with SPSS. A P-value less than 0.05 was considered 
statistically significant. Box and whisker plots of the data 
were prepared by GraphPad Prism for Windows, version 5.0 
(GraphPad Software, San Diego, CA, USA). 
2  Results 
2.1  Establishment of the HCC-related CM protein da-
tabase 
One-dimensional SDS-PAGE was used to separate the CM 
proteins from the cultured HCC tissues. LC-MS/MS analy-
sis and the pFind search program identified CM proteins 
from the 12 samples separately as described in Materials 
and methods. The mean number of identified proteins was 
511, with a range of 271 to 772. Figure S1A shows the 
number of overlapping proteins between the paired tissue 
CM samples. We identified 1365 proteins, with 841 
(61.61%) overlapping proteins and 417 (30.55%) and 107 
(7.84%) differential proteins in the cancerous and noncan-
cerous CM samples, respectively (Figure S1A). File S1 in 
Supporting Information lists detailed information for all 
proteins identified. In addition, we investigated the molecu-
lar weights and pI (isoelectric point) values of the proteins. 
The molecular weights ranged from 6584 to 669735 Da and 
were predominantly in the 1040 kD range (Figure S2A). 
The pI values ranged from 0.99 to 11.85 and were mainly in 
the 4.06.6 range, with a valley around 5.6 (Figure S2B). 
Intriguingly, this pattern coincided with the predicted pro-
teomes of different organisms and implied biological activ-
ity typical of an acid microenvironment in tumor tissues 
[16].  
We compared two plasma proteome datasets with the 
HCC CM proteins: the proteins of the HUPO Plasma Pro-
teome Project [17] and the human plasma proteins identified 
by Anderson et al. [18]. As shown in Figure S1B, 301 and 
173 CM proteins were extracted from the HUPO Plasma 
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Proteome and Anderson’s plasma database, respectively. In 
addition, the HUPO liver proteomic database, which in-
cluded 9020 proteins [19], was compared, which revealed 
that 1077 CM proteins were shared with the HUPO liver 
database. However, 217 proteins in our dataset were not 
present in these three published datasets (Figure S1B).  
2.2  Gene ontology annotation, assignments of path-
ways and network construction for the CM proteins  
The CM proteins were assigned enriched molecular func-
tions, biological processes, and cellular components based 
on GO enrichment. The enriched molecular functions and 
biological processes indicated that the liver was the most 
important metabolic organ. A majority of CM proteins were 
involved in the following molecular functions: hydrolase 
activity (26%), enzyme regulation (9%), and lipid binding 
(6%) (Figure 1A). Biological processes involving the CM 
proteins mainly included protein metabolism (19%), cata-
bolic processes (17%), and amino acid metabolism (6%) 
(Figure 1B). With respect to the cellular distributions of the 
CM proteins, extracellular and membrane proteins ac-
counted for 19% of the total proteins, which are most likely 
secreted into the blood. Many CM proteins were located in 
the cytosol, representing 21% of the total proteins. The re-
maining proteins were distributed in the mitochondria, nu-
cleus, cytoskeleton, Golgi apparatus, and other organelle 
components (Figure 1C). To understand the nature of the 
CM proteins, the preferred pathways of the extracellular 
proteins were classified using the KEGG and PATHART 
pathways databases. Extracellular proteins participated in 
pathways including cell communication, immune system, 
and cell signaling. Furthermore, transforming growth factor 
(TGF)-β signaling is disrupted in HCC [20]. The interaction 
networks for CM proteins involved in the TGF-β signaling 
pathway were investigated by STRING (Figure S3). 
Sub-network analysis revealed that CM proteins, such as 
MMP1, MMP9, OPN, and TIMP1 interacted with the 
TGF-β-induced (TGFBI) protein. In addition, AFP com-
bined with PSG9 participated in the TGF-β signaling path-
way by indirectly interacting with other CM proteins. 
2.3  Detection of selected CM proteins in plasma 
Seven proteins (AFP, MMP1, MMP7, MMP9, OPN, PSG9, 
and TIMP1) were selected based on the TGF-β signaling 
pathway and network analyses. To evaluate the concentra-
tion of CM proteins in plasma, three cohorts including 179 
samples from HCC individuals with HBV infection, 80 
samples from individuals with liver cirrhosis and HBV in-
fection, and 103 samples from healthy controls were en-
rolled. The plasma levels of AFP were significantly higher 
in the HCC patients (Figure 2A, Table 1). In general, 
MMP1, OPN, and PSG9 gradually increased in the plasma 
of healthy controls, liver cirrhosis patients, and HCC pa-
tients. MMP1 and OPN were significantly higher in HCC 
patients than in the healthy controls and liver cirrhosis pa-
tients (Figure 2BD). MMP7, MMP9, and TIMP1 were 
increased in the plasma of liver cirrhosis patients compared 
with the healthy controls and HCC patients (Table 1).  
2.4  Performance of biomarker candidates 
MMP1, OPN, and PSG9 were elevated in HCC samples and 
thus may be potential plasma biomarker candidates. ROC 
analysis evaluated the performance of MMP1, OPN, and 
PSG9. Table 2 shows that the AUCs of MMP1 and OPN but 
not PSG9 had better performance than AFP in discriminat-
ing HCC from healthy controls or cirrhosis (Table 2). When 
HCC was compared with cirrhosis, the AUC for AFP de-
creased, but MMP1 had an even higher AUC (0.945; 95% 
confidence interval (CI): 0.9100.979) (Figure 3A). When 
only HCC samples with AFP levels less than 20 ng mL1 
were included, the MMP1 AUC remained high in discern-
ing HCC from liver cirrhosis (0.948; 95% CI: 0.9120.984) 
(Figure 3B). Moreover, the AUC of OPN (0.911, 95% CI: 
0.8660.957) was greater than that of AFP in discerning 
HCC from liver cirrhosis (Figure 3C). The AUC of OPN 
also remained greater than that of AFP for HCC with AFP 
levels less than 20 ng mL1 (Figure 3D).  
When using the currently recommended clinical cutoff 
for AFP (20 ng mL1) and the best cutoffs for MMP1 (1.72 
ng mL1) and OPN (84.40 ng mL1), as determined using   
 
 
Figure 1  Classification of HCC CM proteins using the gene ontology enrichment tool. A, Molecular function. B, Biological process. C, Cellular compo-
nent. 
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Figure 2  Plasma levels of AFP, MMP1, OPN, and PSG9 in HCC patients, liver cirrhosis patients and healthy controls. A, AFP levels were higher in HCC 
than in liver cirrhosis and healthy controls. B, MMP1 levels were higher in HCC than in liver cirrhosis and healthy controls. C, OPN plasma levels were 
increased in HCC compared with the other groups. D, PSG9 plasma levels were elevated in HCC compared with healthy controls. The box refers to the 25th 
and 75th percentile values, with the line indicating the median values. Points outside the interquartile range are outliers. 
Table 1  Mann-Whitney U-test analysis levels of selected proteins in the plasma of HCC patients, liver cirrhosis patients, and healthy controls 
Protein biomarkers 
Median and standard deviation (ng mL1) 
 





























































<0.001a), <0.001b), <0.001c) 
a) Healthy controls versus HCC. b) Liver cirrhosis versus HCC. c) Liver cirrhosis versus healthy controls. 
the minimal distance to the top-left corner in the ROC curve, 
MMP1 had the best performance, with a sensitivity of 
91.62% (95% CI: 86.6095.20) and a specificity of 91.25% 
(95% CI: 82.8096.40) in differentiating HCC from liver 
cirrhosis (Table 2). For HCC with AFP levels less than 20 
ng mL1, the sensitivity of MMP1 increased to 92.92% 
(95% CI: 86.5096.90) with a specificity of 91.25% (95% 
CI: 82.8096.64) (Table 2). 
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Figure 3  ROC evaluation of the ability of MMP1 and OPN to differentiate HCC patients from liver cirrhosis patients. The AUC is shown with 95% CI. A, 
MMP1 for HCC versus liver cirrhosis. B, MMP1 for HCC with AFP levels less than 20 ng mL1 versus liver cirrhosis. C, OPN for HCC versus liver cirrho-
sis. D, OPN for HCC with AFP levels less than 20 ng mL1 versus liver cirrhosis. AFP is represented by the dashed line, and MMP1 or OPN is represented 
by the solid line. CI, confidence interval.  
Table 2  Area under the ROC curve (AUC), sensitivity and specificity using clinical AFP and MMP1 and OPN optimal cutoff valuesa) 





HCC versus healthy controls 
 





























































HCC (AFP<20 ng mL1) versus liver 
cirrhosis 















a) CI, confidence interval. 
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3  Discussion 
Cancer secretome studies are a good alternative to body 
fluid proteomics. Cancer secretome studies can increase 
analysis specificity while minimizing the number of bi-
omarkers tested, particularly with respect to high-abundance 
proteins found in plasma [21]. One approach for biomarker 
discovery is the analysis of CM from HCC cell lines [10]. 
This proteome is less complex than the full plasma proteo-
me and thus may not adequately represent the pathological 
status of this malignant disease [12]. In the present study, 
primary organ cultures were successfully established from 
cancerous and surrounding noncancerous tissues from HCC 
patients in a serum-free primary culture system. Using 
one-dimensional SDS-PAGE separation coupled with LC- 
MS/MS to analyze CM, 1365 non-redundant proteins were 
ultimately identified, 84% of which were found in the 
HUPO liver and two plasma proteomic datasets. AFP and 
other proteins, including lamin B [22] and heat shock pro-
tein 70 [23], that were elevated in the plasma or tissues of 
HCC patients were identified among the CM proteins. These 
findings confirmed the accuracy of this HCC CM protein 
database and that the quantities of CM proteins extracted 
were sufficient for further analysis. Particular attention was 
placed on extracellular proteins from the CM. These pro-
teins had the highest probability of being observed in the 
circulation and therefore serving as potential biomarkers. In 
general, this approach is a step forward in the discovery of 
potential tumor biomarkers secreted from the tumor micro-
environment. 
This HCC-derived “secretory/released” protein database 
presents new possibilities for understanding liver function 
in a comprehensive and exploratory manner. In this study, 
26% of CM proteins had a molecular function of “hydrolase 
activity”, including epoxide and alcohol hydrolase (Figure 
1A). Moreover, the biological processes of CM proteins 
were enriched for the primary metabolism of proteins, ami-
no acids and carbohydrates (Figure 1B). The molecular 
functions and biological processes of these CM proteins 
reflect the features of liver metabolism. The cellular com-
ponents of the CM proteins most likely to enter the blood 
were classified as “extracellular proteins” and “plasma 
membrane proteins” (Figure 1C). These proteins are re-
leased by the classical secretion mechanism or are shed 
from the cell surface. Because of cell lysis and other 
non-classical secretion mechanisms, some intracellular pro-
teins, such as actin, carbonyl reductase and glyceralde-
hyde-3-phosphate dehydrogenase, were present in the CM 
[8]. In addition, 217 differential proteins, such as the liver 
form of glycogen phosphorylase, may participate in specific 
HCC-related processes (Figure S1B). 
A thorough study with extensive follow-up validation of 
the selected proteins was then performed using plasma 
samples from a relatively large cohort of patients with HCC 
and liver cirrhosis that were chronically infected with HBV. 
The selected proteins were involved in TGF-β signaling 
pathways. TGF-β is a critical regulator of cell renewal, dif-
ferentiation, and survival and is commonly deregulated in 
HCC. The suppression of TGF-β is an early event during 
hepatocarcinogenesis. Hepatitis B virus X proteins shift 
hepatic TGF-β signaling from tumor suppression to onco-
genesis in patients with chronic HBV infection [24]. Thus, 
plasma biomarker candidates associated with TGF-β will 
likely help detect HCC in the early stages. OPN has been 
reported to promote oncogenesis and tumor cell invasion in 
HCC [25]. In this study, OPN was demonstrated to be a 
potential biomarker for the detection of HCC. This finding 
is consistent with a previous report suggesting OPN was 
more sensitive than AFP as a biomarker, and was a marker 
of early-stage HCC [26]. In addition, up-regulated OPN has 
been shown to indicate a poor prognosis for HCC [27]. 
PSG9 belongs to the carcinoembryonic antigen family and 
is a highly glycosylated protein that is deregulated during 
colorectal carcinogenesis [28]. PSG1 regulates immunore-
actions and has proangiogenic properties [29]. Furthermore, 
PSG9 interacts with AFP and is involved in the TGF-β sig-
naling pathway, based on network analysis (Figure S3). 
Because most HCCs arise in the background of chronic cir-
rhosis, the plasma levels of PSG9 were elevated in patients 
with liver cirrhosis in this study (Figure 2), indicating that 
increased PSG9 levels can serve as a biomarker of liver 
cirrhosis.  
MMPs are the principal mediators of alterations observed 
in the microenvironment during cancer progression [30]. 
Because MMPs regulate the important pathway of extracel-
lular matrix turnover, high plasma levels of MMP7, MMP9, 
and TIMP1 in cirrhosis were observed, suggesting their 
involvement in the progressive accumulation of extracellu-
lar matrix proteins following liver injury [31]. The most 
important finding in the current study was the identification 
of MMP1 as a diagnostic biomarker for HCC. A previous 
meta-analysis demonstrated that MMP1 increased the risk 
of cancer metastasis [32]. Decock et al. [33] reported that 
plasma levels of MMP1 were lower in breast cancer patients 
than in healthy controls, and plasma levels of MMP1 were 
elevated in lung cancer patients [34]. We demonstrated that 
MMP1 plasma levels were significantly increased in HCC, 
indicating that MMP1 plasma levels vary among different 
types of human tumors. We confirmed the strong discrimi-
natory power of MMP1 to distinguish HCC patients from 
healthy controls and cirrhosis patients. Overall, the sensitiv-
ity and specificity of MMP1 in differentiating HCC cases 
from liver cirrhosis cases were better than those of AFP and 
OPN. The best performance of MMP1 was obtained when 
distinguishing HCC patients from liver cirrhosis patients, 
and ROC analysis revealed its improved performance in 
discerning HCC with AFP levels less than 20 ng mL1. 
These findings indicate that MMP1 could be used as a bi-
omarker to improve HCC diagnosis at an early stage. This is 
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an important first step in the evaluation of MMP1 as an 
HCC marker. However, this study had some limitations, 
such as not using samples of long term HBV infection and 
not detecting dynamic changes in long-term follow-up 
plasma before HCC diagnosis. Further analysis will be 
needed to validate this biomarker in large-scale cohorts of 
HBV carriers. 
In conclusion, this study reported an HCC secretome da-
tabase of 1365 CM proteins, which was established based 
on a serum-free primary culture model. The data indicate 
this HCC cancer-related protein database provides a re-
source of potential biomarkers for diagnosis of this malig-
nant disease. Among these validated biomarker candidates, 
MMP1 and OPN, which have better AUCs than AFP, may 
be potential plasma biomarkers to improve HCC diagnosis. 
We thank Dr. Feng Lin for data analysis, and Dr. An Ning for his attentive 
review of this manuscript. We also thank Dr. Fu Yan and his group (Insti-
tute of Computing Technology, Chinese Academy of Sciences) for their 
generous support with the valuable pFind 2.4 software. This work was 
supported by the National Natural Science Foundation of China 
(81172035, 30973388), the National Excellent Doctoral Dissertation of 
China (2007B68), the National High Technology Research and Develop-
ment Program of China (2012AA020206), and the Basic Research Pro-
gram of the Cancer Hospital, PUMC & CAMS (JK2009B08, LC2009B45). 
The authors declare no competing financial interest. 
1 Jemal A, Bray F, Center M M, et al. Global cancer statistics. CA 
Cancer J Clin, 2011, 61: 69–90 
2 Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of 
hepatitis B in China—declining HBV prevalence due to hepatitis B 
vaccination. Vaccine, 2009, 27: 6550–6557 
3 Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence 
after liver resection for hepatocellular carcinoma: prognostic and 
therapeutic implications. Ann Surg, 2006, 243: 229–235 
4 Shimada K, Sakamoto Y, Esaki M, et al. Analysis of prognostic 
factors affecting survival after initial recurrence and treatment 
efficacy for recurrence in patients undergoing potentially curative 
hepatectomy for hepatocellular carcinoma. Ann Surg Oncol, 2007, 14: 
2337–2347 
5 Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a 
valuable serum marker for hepatocellular carcinoma. Gut, 2010, 59: 
1687–1693 
6 States D J, Omenn G S, Blackwell T W, et al. Challenges in deriving 
high-confidence protein identifications from data gathered by a 
HUPO plasma proteome collaborative study. Nat Biotechnol, 2006, 
24: 333–338 
7 Meng R, Gormley M, Bhat V B, et al. Low abundance protein 
enrichment for discovery of candidate plasma protein biomarkers for 
early detection of breast cancer. J Proteomics, 2011, 75: 366–374 
8 Makridakis M, Vlahou A. Secretome proteomics for discovery of 
cancer biomarkers. J Proteomics, 2010, 73: 2291–2305 
9 Planque C, Kulasingam V, Smith C R, et al. Identification of five 
candidate lung cancer biomarkers by proteomics analysis of 
conditioned media of four lung cancer cell lines. Mol Cell Proteomics, 
2009, 8: 2746–2758 
10 Polisetty R V, Gupta M K, Nair S C, et al. Glioblastoma cell 
secretome: analysis of three glioblastoma cell lines reveal 148 
non-redundant proteins. J Proteomics, 2011, 74: 1918–1925 
11 Xiao T, Ying W, Li L, et al. An approach to studying lung 
cancer-related proteins in human blood. Mol Cell Proteomics, 2005, 4: 
1480–1486 
12 Zhang Y, Xu B, Liu Y, et al. The ovarian cancer-derived secretory/ 
releasing proteome: a repertoire of tumor markers. Proteomics, 2012, 
12: 1883–1891 
13 Lechner J F, LaVeck M A. A serum-free method for culturing normal 
human bronchial epithelial cells at clonal density. J Tissue Cult 
Methods, 1985, 9: 43–48 
14 Shen Z, Li P, Ni R J, et al. Label-free quantitative proteomics 
analysis of etiolated maize seedling leaves during greening. Mol Cell 
Proteomics, 2009, 8: 2443–2460 
15 Sun H, Fang H, Chen T, et al. GOFFA: gene ontology for functional 
analysis—a FDA gene ontology tool for analysis of genomic and 
proteomic data. BMC Bioinformatics, 2006, 7(Suppl 2): S23 
16 Wu S, Wan P, Li J, et al. Multi-modality of pI distribution in whole 
proteome. Proteomics, 2006, 6: 449–455 
17 Omenn G S, States D J, Adamski M, et al. Overview of the HUPO 
Plasma Proteome Project: results from the pilot phase with 35 
collaborating laboratories and multiple analytical groups, generating 
a core dataset of 3020 proteins and a publicly-available database. 
Proteomics, 2005, 5: 3226–3245 
18 Anderson N L, Polanski M, Pieper R, et al. The human plasma 
proteome: a nonredundant list developed by combination of four 
separate sources. Mol Cell Proteomics, 2004, 3: 311–326 
19 Chinese Human Liver Proteome Profiling Consortium. First insight 
into the human liver proteome from PROTEOME(SKY)- LIVER(Hu) 
1.0, a publicly available database. J Proteome Res, 2010, 9: 79–94 
20 Lin L, Amin R, Gallicano G I, et al. The STAT3 inhibitor NSC 
74859 is effective in hepatocellular cancers with disrupted TGF-beta 
signaling. Oncogene, 2009, 28: 961–972 
21 Pavlou M P, Diamandis E P. The cancer cell secretome: a good 
source for discovering biomarkers? J Proteomics, 2010, 73: 
1896–1906 
22 Sun S, Xu M Z, Poon R T, et al. Circulating Lamin B1 (LMNB1) 
biomarker detects early stages of liver cancer in patients. J Proteome 
Res, 2010, 9: 70–78 
23 Luk J M, Lam C T, Siu A F, et al. Proteomic profiling of 
hepatocellular carcinoma in Chinese cohort reveals heat-shock 
proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated 
prognostic values. Proteomics, 2006, 6: 1049–1057 
24 Murata M, Matsuzaki K, Yoshida K, et al. Hepatitis B virus X protein 
shifts human hepatic transforming growth factor (TGF)-beta 
signaling from tumor suppression to oncogenesis in early chronic 
hepatitis B. Hepatology, 2009, 49: 1203–1217 
25 Takafuji V, Forgues M, Unsworth E, et al. An osteopontin fragment 
is essential for tumor cell invasion in hepatocellular carcinoma. 
Oncogene, 2007, 26: 6361–6371 
26 Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a 
novel marker for early hepatocellular carcinoma. Hepatology, 2012, 
55: 483–490 
27 Sun J, Xu H M, Zhou H J, et al. The prognostic significance of 
preoperative plasma levels of osteopontin in patients with TNM 
stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2010, 
136: 1–7 
28 Salahshor S, Goncalves J, Chetty R, et al. Differential gene 
expression profile reveals deregulation of pregnancy specific beta1 
glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer, 
2005, 5: 66 
29 Lisboa F A, Warren J, Sulkowski G, et al. Pregnancy-specific 
glycoprotein 1 induces endothelial tubulogenesis through interaction 
with cell surface proteoglycans. J Biol Chem, 2011, 286: 7577–7586 
30 Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: 
regulators of the tumor microenvironment. Cell, 2010, 141: 52–67 
31 Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression 
signature of mild fibrosis in patients with chronic hepatitis C. 
Gastroenterology, 2005, 129: 2064–2075 
32 Liu D, Guo H, Li Y, et al. Association between polymorphisms in the 
promoter regions of matrix metalloproteinases (MMPs) and risk of 
cancer metastasis: a meta-analysis. PLoS ONE, 2012, 7: e31251 
33 Decock J, Hendrickx W, Vanleeuw U, et al. Plasma MMP1 and 
MMP8 expression in breast cancer: protective role of MMP8 against 
646 Yang L, et al.   Sci China Life Sci   July (2013) Vol.56 No.7 
lymph node metastasis. BMC Cancer, 2008, 8: 77 
34 Li M, Xiao T, Zhang Y, et al. Prognostic significance of matrix 
metalloproteinase-1 levels in peripheral plasma and tumour tissues of 
lung cancer patients. Lung Cancer, 2010, 69: 341–347 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
 
Supporting Information 
Table S1  Clinicopathological characteristics of six paired samples from HCC patients 
Figure S1  Proteins identified in the CM from six paired HCC tissues. A, Total number of proteins identified from the CM of paired cancerous (C) and 
surrounding noncancerous (N) tissues. B, The Venn diagram represented the comparison of HCC CM proteins with the published human proteomes.  
Figure S2  Molecular weight (A) and pI (B) distribution of the identified CM proteins. 
Figure S3  The interaction sub-network of the CM proteins involved in TGF-β signaling pathways. The proteins AFP, MMP1, MMP7, MMP9, OPN 
(SPP1), PSG9, and TIMP1 were subsequently validated as potential HCC biomarkers. 
File S1  The information of protein identifications in HCC CM 
The supporting information is available online at life.scichina.com and www.springerlink.com. The supporting materials 
are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains en-
tirely with the authors. 
 
 
